Novavax, Inc. announced today that CPL Biologicals Pvt. Ltd., the new joint venturebetween Cadila Pharmaceuticals in India, has begun construction of astate-of-the-art manufacturing facility that will be used to produce pandemicand seasonal influenza vaccines. CPL Biologicals will utilize Novavax’svirus-like particle (VLP) vaccine technology to produce commercial-scalequantities of VLP-based influenza vaccines using Novavax’s innovativedisposable manufacturing solution. The CPL Biologicals facility is expectedto be operational within four months and should be capable of producing over60 million doses annually at full capacity. This facility will also be usedto produce other novel vaccines being developed by CPL Biologicals, based onNovavax’s VLP vaccine technology. “This new facility is being 100% supported financially by our partner,Cadila Pharmaceuticals Ltd. We anticipate creating sufficient capacity for CPLBiologicals to sell influenza vaccines in India and at the same time become apotential supplier to Novavax for sale of vaccines in other markets whereNovavax maintains complete commercial rights,” commented John Trizzino, SeniorVice President, International and Government Alliances for Novavax and InterimChief Executive Officer of CPL Biologicals. “We believe this model will showhow an efficient and scalable vaccine platform can help address the growingdemand for pandemic and seasonal influenza vaccines. Moreover, theconstruction of this manufacturing facility is consistent with Novavax’sstrategy to establish regional partnerships and regional manufacturingcapabilities that allow our VLP influenza vaccines to be licensed,manufactured and sold throughout the world.”
